Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Multicenter Automatic Defibrillator Implantation Trial - Reduce Inappropriate Therapy (MADIT-RIT)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Boston Scientific Corporation
ClinicalTrials.gov Identifier:
NCT00947310
First received: July 27, 2009
Last updated: March 4, 2013
Last verified: March 2013

July 27, 2009
March 4, 2013
September 2009
August 2012   (final data collection date for primary outcome measure)
Inappropriate ICD Therapy [ Time Frame: Average of 1.4 years follow-up ] [ Designated as safety issue: No ]
First occurance of inappropriate therapy (either anti-tachycardia pacing or shock)
Not Provided
Complete list of historical versions of study NCT00947310 on ClinicalTrials.gov Archive Site
  • All-cause Mortality [ Time Frame: Average 1.4 years of follow-up ] [ Designated as safety issue: Yes ]
  • Syncope [ Time Frame: Average of 1.4 years follow-up ] [ Designated as safety issue: Yes ]
    First episode of syncope
Not Provided
Not Provided
Not Provided
 
Multicenter Automatic Defibrillator Implantation Trial - Reduce Inappropriate Therapy
IDE-Exempt: Multicenter Automatic Defibrillator Implantation Trial - Reduce Inappropriate Therapy

This study will assess the impact of higher rate cutoffs and longer delays than standard programming on inappropriate therapy in primary prevention ICD and CRT-D patients.

The purpose of the MADIT-RIT trial is to compare the time to first inappropriate therapy using high rate cutoff and/or long delay in primary prevention patients receiving an ICD or CRT-D device compared to standard programming.

Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Primary Prevention of Sudden Cardiac Arrest
  • Device: Standard ICD programming
    Standard ICD programming
  • Device: High rate cutoff
    Programming of a high rate cutoff
  • Device: Long delay
    Programming of a prolonged delay
  • Experimental: A
    Standard ICD Programming
    Intervention: Device: Standard ICD programming
  • Experimental: B
    High rate cutoff
    Intervention: Device: High rate cutoff
  • Experimental: C
    Long ICD duration delay
    Intervention: Device: Long delay

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1500
December 2012
August 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Primary prevention patient with ischemic or non-ischemic heart disease who meets current guidelines for dual-chamber ICD or CRT-D device therapy
  • Patient in sinus rhythm
  • Patient on stable optimal pharmacologic therapy for the cardiac condition or who has developed a recent ICD indication that necessitates ICD therapy concurrent with the optimization of pharmacologic therapy
  • Patient ≥ 21 years of age, or legal representative, willing and capable of giving informed consent

Exclusion Criteria:

  • Patient with an implanted pacemaker or CRT-P
  • Patient with existing ICD or CRT-D device components
  • Patient with a history of VT or VF
  • Patient with permanent or chronic AF, or cardioversion for AF, within the past three calendar months before enrollment
  • Patient with coronary artery bypass graft surgery or percutaneous coronary intervention within the past three calendar months prior to enrollment
  • Patient with enzyme-positive myocardial infarction within the past three calendar months prior to enrollment
  • Patient with angiographic evidence of coronary disease who are candidates for coronary revascularization and are likely to undergo coronary artery bypass graft surgery or percutaneous coronary intervention in the foreseeable future
  • Patient with second or third degree heart block
  • Patient in NYHA Class IV
  • Patient who is pregnant or plans to become pregnant during the course of the trial
  • Patient with irreversible brain damage from preexisting cerebral disease
  • Patient with presence of any disease, other than the patient's cardiac disease, associated with a reduced likelihood of survival for the duration of the trial, e.g., cancer, uremia, liver failure, etc.
  • Patient with chronic renal disease with BUN ≥ 50mg/dl or creatinine ≥ 2.5 mg/dl
  • Patient participating in any other clinical trial
  • Patient unwilling or unable to cooperate with the protocol
  • Patient who lives at such a distance from the clinic that travel for follow-up visits would be unusually difficult
  • Patient who does not anticipate being a resident of the area for the scheduled duration of the trial
  • Patient unwilling to sign the consent for participation
  • Patient whose physician does not allow participation
Both
21 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00947310
MADIT-RIT
Yes
Boston Scientific Corporation
Boston Scientific Corporation
Not Provided
Principal Investigator: Arthur J Moss, MD University of Rochester
Boston Scientific Corporation
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP